XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 25.44

-4.1%

3:11 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (6715)	7/22/1998 8:45:00 PM
From: Robert S.	Read Replies (2) of 17367

Thanks RobertK for your response regarding BPI costs but I am still interested in ascertaining actual projected costs. To revisit a question I posted earlier: George, upon hearing the Incyte license deal, I expected a greater reaction from the Street than thus far exhibited. A question pertaining to the Incyte/Xoma licensing agreement is why did Incyte agree to this arrangement for such an insignificant financial package? The prognostications presented here and elsewhere indicated that the potential market for BPI is large, yet, Incyte does not seem to share this view. You stated the sum ($11.5 M) is advantageous for Xoma yet this doesn't explain things from Incyte's perspective. Any thoughts from you (or others) are appreciated.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next